Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.33 |
| ▸ | CHRNG | P07510 | 2/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.33 |
| ▸ | CHRND | Q07001 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451775 | 0.91 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL2913382 | 0.89 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL26291025 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL25989709 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL26309023 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23567637 | 0.82 | CHRNB2 (0.61) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6937141 | 0.82 | CHRNB2 (0.61) | CHRNB2CHRNA4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14003850 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14364780 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29761232 | 0.78 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070224690-A1 | VARENICLINE STANDARDS AND IMPURITY CONTROLS | PFIZER INC | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CHRNB2 4478/4885CHRNA4 4066/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.